What's new? Log in Free sign up

Filing search / Lineage Cell Therapeutics, Inc. / "Litigation"

Search information

Lineage Cell Therapeutics, Inc.

Companies

"Litigation"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

216 results

Newest first Best match first

LCTX Lineage Cell Therapeutics, Inc.

Quarterly report

such litigation without the prior written consent of Hadasit, which consent shall not be unreasonably withheld or delayed. 10.3. Hadasit and HMO shall … , which shall not be unreasonably withheld or delayed. Any proceeds received by the Company in any such litigation shall first be applied to cover out

8 Aug 24

4:15pm

LCTX Lineage Cell Therapeutics, Inc.

Quarterly report

to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than … consolidated balance sheet because the achievement and timing of these events are not fixed and determinable. Litigation – General From time to time, we

8 Aug 24

4:15pm

LCTX Lineage Cell Therapeutics, Inc.

Quarterly report

to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than … balance sheet because the achievement and timing of these events are not fixed and determinable. Litigation – General From time to time, we are subject

9 May 24

4:15pm

LCTX Lineage Cell Therapeutics, Inc.

Entry into a Material Definitive Agreement

laws or public policy considerations in respect thereof. (q)No Litigation. Except as set forth in the Registration Statement or the Prospectus … such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental Authority has taken

LCTX Lineage Cell Therapeutics, Inc.

Shelf registration

TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE. Section 13.06

7 Mar 24

5:17pm

7daa85qdlcu1sq glb

7 Mar 24

4:21pm

7 Mar 24

4:21pm

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

qvjupd3yirb9 e7c9632

Prospectus supplement for primary offering

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

1aaqqxqvawk0042

Quarterly report

9 Nov 23

4:15pm

Quarterly report

10 Aug 23

4:16pm

9kvk mt4ls3km49bqvk3

LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL

3sx4m3chx8cz2lw xhf

Quarterly report

11 May 23

4:15pm

LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Quarterly report

10 Nov 22

4:16pm

odigbyjy67nr m0rzg

LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

xfqp6n 8yh2xityt3r

Quarterly report

11 Aug 22

4:16pm

fr7ops3mmv ndzw97fyu

Departure of Directors or Certain Officers

fk48fs8e1ssfv56nw

Submission of Matters to a Vote of Security Holders

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.